TORONTO, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is…
Figure Initial treatment imaging from first patient treated in the ReSPECT-GBM Phase 2b trialAUSTIN, Texas, Jan. 18, 2023 (GLOBE NEWSWIRE)…
CINCINNATI, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a…
Record revenue of approximately $2.5 million for the three months ended December 31, 2022 and $8.5 million for full-year 2022Revenue…
SAN FRANCISCO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Adaptive Research, an integrated clinical trial site organization with a unique purpose…
-- Fifth Center of Excellence added in multi-center, company-sponsored, openobservational interventional trial to evaluate the impact of subjects’…
BEDFORD, Mass., and SHANGHAI, China, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Frontera Therapeutics, a global clinical-stage biotechnology company that seeks…
A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment OptionsNEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ovid…
REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl…